Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
LipoKnoxa™ Human BDNF shRNA Lentiviral Particle (Silencing)
Cat. No.:
V0126XX441
Species:
Human
Target Gene:
BDNF
Vector System:
Lentiviral
Modulation Type:
Silencing (shRNA)
SPECIFIC INQUIRY
Add to basket
| Sub Cat. No. | TargetSeq | Region | Inquiry |
|---|---|---|---|
| V0126XX441-1 | GTATGTACATTGACCATTAAA | CDS | Inquiry |
| V0126XX441-2 | TTTCCTTACTATGGTTATTTC | CDS | Inquiry |
| V0126XX441-3 | ACAGTGGTTCTACAATCTATT | 3' UTR | Inquiry |
| V0126XX441-4 | Other | Inquiry |
Product Overview
Description:
LipoKnoxa™ Human BDNF shRNA Lentiviral Particle (Silencing) targets BDNF, which plays a pivotal role in suppressing food intake. Silencing BDNF through our dual-strategy shRNA platform (U6 and miR30) helps researchers model feeding behavior and neuroplasticity. We ensure a high-performing gene-silencing solution via thorough QC validation, including high-precision titer verification and negative results for sterility and mycoplasma.
Production Cell Line:
HEK293T
Promoter:
U6; CMV; EF1α; CAG; UBC
Product Availability:
Produced Upon Order
Specification
Titer Test:
qPCR
Insert Verification:
Comprehensive sequencing and PCR analyses were performed to verify the accurate genomic sequence of all viral preparations.
Sterility Test:
Confirmed sterile via rigorous microbial analysis; free of bacterial and fungal contamination.
Mycoplasma Test:
Rigorous quality control testing has confirmed the absence of mycoplasma contamination in this viral preparation.
Other QC:
Customized supplementary testing and in vitro/in vivo assessments are available to verify post-silencing gene expression and biological functionality, ensuring the viral preparations meet the specific potency requirements of your gene interference project.
Storage:
Store at -80°C for long-term preservation. Immediate transfer upon delivery is required to prevent loss of viral activity.
Stability:
Shelf life: 6–12 months at -80°C (extended stability up to 2 years). Post-thaw: Stable at 4°C for 2–3 weeks without significant degradation of functional titers.
Shipping Condition:
Products are delivered on dry ice to maintain the cold chain. Upon arrival, please ensure the presence of dry ice and transfer the vials immediately to -80°C storage.
Handling Notes:
Avoid repeated freeze-thaw cycles. Aliquot into low-protein-binding tubes immediately after receipt to maintain optimal activity. For safety and contamination control, all viral handling must be performed inside a biosafety cabinet.
Intended Use:
This product is intended for research use only and is not for use in diagnosis or therapeutic applications.
Product Disclaimer:
We ensure product integrity through rigorous QC, but we do not guarantee results in specific research contexts. Proper storage, handling, and total compliance with biosafety laws and safety protocols remain the sole responsibility of the user.
Target Profile
Gene Name:
BDNF
Full Name:
Brain derived neurotrophic factor
Gene Symbol:
ANON2; BULN2
Gene ID:
627
RefSeq ID-1:
NP_001137277.1
RefSeq ID-2:
NM_001143805.1
Summary:
BDNF is a pivotal protein belonging to the nerve growth factor family. Synthesized as a preproprotein, it undergoes necessary proteolytic processing to yield the mature, bioactive form. In the adult brain, BDNF is crucial for promoting neuronal survival, plasticity, and differentiation by binding to its cognate receptor (TrkB). This neurotrophin plays a key modulatory role in the stress response and the underlying biology of mood disorders like depression. Pathologically, reduced BDNF expression is commonly observed in patients suffering from severe neurodegenerative conditions, including Alzheimer's, Parkinson's, and Huntington's disease.